66 results about "Malarial parasite" patented technology

Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

The present invention belongs to the field of biomedical technology and specifically relates to the use of Akkermansia muciniphila in ameliorating and treating cerebral malaria caused by Plasmodium berghei. This study evaluated the efficacy of Akkermansia muciniphila alone or in combination with adjuvant drugs (dihydroartemisinin, rapamycin, and atorvastatin) in ameliorating and treating cerebral malaria in a mouse cerebral malaria model. The results suggest that the bacteria, whether used alone or in combination with other drugs, effectively improved mouse behavior, immune pathological damage to various organs, reduced parasitemia, and prolonged mouse survival, demonstrating its effectiveness in treating cerebral malaria in mice compared to using the drugs alone. Because Akkermansia muciniphila is a common probiotic in the human gut, the three drugs used in this study (dihydroartemisinin, rapamycin, and atorvastatin) are all currently in clinical use. Clinical translation for the treatment of human cerebral malaria caused by Plasmodium falciparum is highly feasible and can also shorten the conversion time. This study proposes for the first time the concept of bacterial-drug synergy, whereby probiotics can complement drug treatments, and provides a solution for the treatment of human cerebral malaria based on this concept.

According to the purposes of the present disclosure, as embodied and broadly described herein, the present disclosure relates, in one aspect, to scaffold molecules that exhibit potent anti-malarial activity against a variety of Plasmodium strains at different stages of a parasite, such as the red and infrared stages, and pharmaceutical compositions comprising the scaffold molecules. In one aspect, these compounds are tetrahydroacridones having Structure I described herein. In another aspect, the compounds described herein may be used to treat or prevent malaria in a subject.

The application discloses a kit for rapidly identifying malignant plasmodium based on an RPA-CRISPR / Cas12a fluorescence system and belongs to the field of detection and testing. The kit comprises a malignant plasmodium RPA specific primer pair, a crRNA fragment, a fluorescence reporter probe, and a buffer and Cas12a protein for a CRISPR reaction. The application is based on RPA technology, CRISPR / Cas12a technology and fluorescence detection technology, and a kit and a detection method for rapidly, accurately, simply and specifically detecting and identifying malignant plasmodium are constructed. The kit and the detection method can be used for detecting malignant plasmodium in a wild or clinical environment, especially in a country with limited resources, and the detection method does not require expensive instruments and equipment and a professional standard laboratory, and therefore has important significance for malaria monitoring, diagnosis and prevention and control.

This invention provides the application of Pulsatilla saponin B4 in the preparation of antimalarial drugs, which can significantly improve weight loss, peripheral blood parasitemia, and survival rate in mice infected with lethal Plasmodium. Its mechanism of action is not to directly kill Plasmodium, but to regulate the host immune system, including activating T / B cell immune responses, upregulating pro-inflammatory factors and interferon signaling pathways, and downregulating Arg1 expression. At the same time, Pulsatilla saponin B4 can alleviate immunopathological damage to organs such as the spleen and liver, restore the homeostasis of the spleen's immune microenvironment, and protect the normal structure of tissues. As a natural product, this compound has the characteristics of multiple targets and low toxicity, and has the dual advantages of anti-infection and immune homeostasis regulation, showing good prospects for clinical application and translation.

In one aspect, the present invention relates to compounds that inhibit asexual erythroid parasites (PfABS) of Plasmodium falciparum. In one aspect, these compounds exhibit sub-mmol potency against the erythroid phase of Plasmodium falciparum and other Plasmodium. In another aspect, these compounds are soluble in aqueous solutions at pH 7.4, making them suitable for oral administration by patients. Also disclosed are methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of treating or preventing malaria using the compounds. This abstract is intended as a scanning tool for a field-specific search and is not intended to be limiting of the present disclosure.

Disclosed herein are methods and compositions for treating and / or preventing Plasmodium falciparum malaria by administering a compound that mimics the binding of anti-Plasmodium falciparum Glutamic Acid Rich Protein (PfGARP).

In a method for diagnosing dengue fever and malaria, DNA extracted from a sample is added to a composition including a first primer set of nucleotide sequences of SEQ ID Nos. 1 to 6 and a second primer set of nucleotide sequences of SEQ ID Nos. 7 to 11, a loop-mediated isothermal amplification (LAMP) reaction of the DNA is performed to produce a colorimetric change, an image of the reaction tube is captured, the image is analyzed using a trained artificial intelligence model to determine whether the reaction indicates a positive or negative result for Dengue virus or Plasmodium falciparum.

The present invention discloses a malaria blood smear cell detection and segmentation method based on Mask R-CNN, which realizes the detection and segmentation of malarial parasites and red blood cells in thin blood smear images, including: using VoVNet-57 as the backbone feature extraction network to extract richer thin blood smear image features; improving the feature pyramid network structure to make full use of the cell classification information rich in high-level features to enhance the representation ability of the underlying features; using the attenuation function to improve the traditional non-maximum suppression algorithm to reduce the cases of missed detection due to cell stacking; reconstructing the cell classification loss function to improve the problem of low detection accuracy due to imbalanced cell categories. The method proposed in the present invention can effectively improve the accuracy of the Mask R-CNN network model for cell detection and segmentation in thin blood smear images, providing a scientific basis for malaria diagnosis.

An immunogen generally includes an immunogenic carrier that includes a virus-like particle (VLP) and an antigenic Anopheles spp. TRIO peptide that includes amino acids VDDLMAKFN (SEQ ID NO:1) or AANLRDKFN (SEQ ID NO:5) linked to the immunogenic carrier. The immunogen can be formulated into a composition such as vaccine. The composition or vaccine may be used to treat a subject having, or at risk of having malaria. The composition or vaccine may be used to treat a subject having Plasmodium falciparum blood stage parasitemia.

The present invention relates to a vaccine composition for preventing malaria, comprising, as an active ingredient, an elongation factor-2 (EF-2) recombinant protein derived from Plasmodium falciparum and, more specifically, to a vaccine composition for preventing malaria, comprising, as an active ingredient, EF-2 recombinant peptides derived from Plasmodium falciparum consisting of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2, respectively, and use thereof.

The present invention provides an antimalarial composition comprising arjunetin and artemisinin. The composition exhibits synergistic antimalarial effect against malaria causing Plasmodium species including Plamsodium falciparum, P berghe species. The composition comprising Arjunetin and Artemisinin demonstrated potent antimalarial activity in vivo and in vitro with better survival and low parasite burden in the blood.

The invention belongs to the technical field of biological detection, and particularly relates to a hybridoma cell strain 3F9 capable of secreting a plasmodium CSP recombinant protein monoclonal antibody and application of the hybridoma cell strain 3F9. The hybridoma cell strain 3F9 is preserved in the China General Microbiological Culture Collection Center on August 21, 2024, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C2024244; the monoclonal antibody secreted by the hybridoma cell strain 3F9 has good specificity on the plasmodium CSP protein, an ELISA detection method established by using the monoclonal antibody can be used for detecting the plasmodium CSP protein and has good specificity, the detection sensitivity is as low as 0.25 mu g / ml, and the monoclonal antibody has important significance on plasmodium CS P protein detection and plasmodium disease diagnosis.

In one aspect, the disclosure relates to compounds that inhibit Plasmodium falciparum asexual blood stage parasites (PfABS) In one aspect, the compounds exhibit sub-millimolar potency against the intraerythrocytic stages of Plasmodium falciparum and other Plasmodium species. In another aspect, the compounds are soluble in aqueous solutions at pH 7.4, making them suitable for oral administration to patients. Also disclosed are methods of making the compounds, pharmaceutical compositions comprising the same, and methods of treating or preventing malaria using the same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The application discloses a new application of a triazoloquinoline derivative or a pharmaceutically acceptable salt or hydrate thereof. The triazoloquinoline derivative can inhibit the expression of an invasion gene PfAP2-O5, block the invasion of Plasmodium falciparum into red blood cells, affect the growth and development of the Plasmodium falciparum, and achieve a killing effect of the Plasmodium falciparum, so that the triazoloquinoline derivative can be used as an inhibitor of PfAP2-O5, a drug for inhibiting Plasmodium falciparum, or a drug for preventing or treating malaria.

The invention relates to the field of molecular vaccinology, in particular to a vaccine aiming at severe malaria, and further relates to a multi-epitope fusion antigen vaccine derived from plasmodium falciparum STEVOR protein as well as preparation and application of the multi-epitope fusion antigen vaccine. The multi-epitope fusion antigen vaccine contains at least two amino acid fragments in a B cell epitope, a CD4 and T cell epitope and a CD8 and T cell epitope. The MEFA vaccine targeting STEVOR protein SC structural domain conservative immunodominant epitopes has broad spectrum, can realize 97.15% global HLA coverage rate through the conservative epitopes, can synchronously induce IgG antibody and CD4 + / CD8 + T cell response, is safe, has no toxicity / sensitization, and has good in-vivo and in-vitro stability (the mammalian half-life period gt; further, the strain is used for inducing wide immune response for resisting severe malaria, and is suitable for large-scale production of an escherichia coli or yeast expression system.

The invention relates to application of a scavenger receptor A antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention and treatment. Aiming at the technical problem that in the prior art, the drug resistance of plasmodium to drugs and the resistance of mosquito vector to insecticides are increasingly serious, so that the malaria propagation control effect is reduced, the invention provides a scavenger receptor A antibody which is specifically combined with a scavenger receptor A on the surface of macrophage to inhibit the phagocytic function of the scavenger receptor A, so that the control effect of malaria propagation is improved. Therefore, the proliferation of antimalarial active bacteria (such as Elizabeth, shigella sonnei or klebsiella oxytoca) in the stomach of the anopheles is promoted, and the development of plasmodium in the midgut of the anopheles is indirectly blocked. The antibody can be used alone or in combination with a Pfs25 antibody. The anopheles infection rate and the number of oocysts are remarkably reduced (for example, the infection rate is reduced from 81.7% to 6%), an eco-friendly biological control mode which is not prone to drug resistance is provided, and a new strategy is provided for malaria transmission blocking.

The invention relates to the technical field of gene engineering and nucleic acid detection, and particularly discloses a plasmodium multiple nucleic acid detection kit and a matched artificial chromosome engineering bacterium quality control product. The kit comprises a plasmodium falciparum specific primer probe group, a plasmodium vivax specific primer probe group, a plasmodium malaria malaria specific primer probe group and a plasmodium ovale specific primer probe group, and other PCR reaction system components, and can realize high-specificity, high-sensitivity and high-accuracy typing detection of target genes of the four kinds of plasmodium. The establishment of a fluorescence PCR and digital PCR quantitative detection gradient dilution standard curve and the performance verification requirements of a nucleic acid extraction kit are met. The quality control product is escherichia coli engineering bacteria carrying recombinant artificial chromosomes, 18S rRNA gene consistency sequence fragments of plasmodium falciparum, plasmodium vivax, plasmodium malaria and plasmodium ovale are integrated in the chromosomes of the escherichia coli engineering bacteria, and the quality control product has good species specificity, nuclease tolerance, structural stability and simulation sample extraction characteristics.

The invention discloses an antibody for resisting plasmodium or histidine-rich protein-II of the plasmodium and application of the antibody, and relates to the field of antibodies. The anti-plasmodium or histidine-rich protein-II antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of plasmodium or histidine-rich protein-II, and has good affinity or activity.

This invention discloses novel applications of hexahydroquinoline derivatives or their pharmaceutically acceptable salts or hydrates. These hexahydroquinoline derivatives can inhibit the expression of the invading gene PfAP2-O5, blocking the invasion of erythrocytes by Plasmodium falciparum, affecting its growth and development, and achieving a killing effect on Plasmodium falciparum. Therefore, these hexahydroquinoline derivatives can serve as inhibitors of PfAP2-O5, drugs for inhibiting Plasmodium falciparum, or drugs for the prevention or treatment of malaria.

This disclosure relates to a compound represented by formula I:(I) and a method for treating malaria parasitic infection, the method comprising administering the compound represented by formula I or a pharmaceutically acceptable salt thereof to a person in need of such treatment. [Formula 1] TIFF2026520957000151.tif23115

A method of measuring malarial parasitemia includes disposing a sample including red blood cells in liquid form on a sample stage, illuminating the sample with optical radiation, capturing a plurality of images of the sample, and extracting, from the one or more of the plurality of images, a set of red blood cell images. Each red blood cell image is associated with a particular red blood cell. The method also includes for each red blood cell image in the set of red blood cell images, inputting each red blood cell image into a machine learning model and generating, using the machine learning model, a classification related to a malaria parasite lifecycle stage for each of the red blood cells. The method further includes determining the malarial parasitemia for the sample.

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules that exhibit potent antimalarial activity against multiple strains of Plasmodium spp. in the parasite's various stages, such as, for example, the erythrocytic and exoerythrocytic stages, and pharmaceutical compositions comprising same. In one aspect, the compounds are tetrahydroacridinones having the structure I described herein. In another aspect, the compounds described herein can be used to treat or prevent malaria in a subject.

The present invention relates to a multiplex and simultaneous antigen detection kit (200) for the rapid diagnosis of Dengue, Chikungunya, and two forms of Malaria (Plasmodium vivax and Plasmodium falciparum) from whole blood samples. Utilizing vertical flow technology, the kit allows the detection of multiple antigens concurrently, offering faster results with enhanced sensitivity and specificity compared to traditional lateral flow assays. The diagnostic device employs metal nanoparticles and gold conjugates to detect the specific antigens, facilitating co-infection detection without the need for serum or plasma separation.

This application relates to compositions comprising 1-methyl-9H-pyrido[3,4-b]indole or a pharmaceutically acceptable salt thereof for use in reducing or preventing the transmission of malaria and dengue fever, and corresponding methods. This application also relates to 1-methyl-9H-pyrido[3,4-b]indole or a pharmaceutically acceptable salt thereof for use in inhibiting the development of protozoa into ookinetes, oocysts, or sporozoites, and to mosquito baits comprising 1-methyl-9H-pyrido[3,4-b]indole or a pharmaceutically acceptable salt thereof and one or more sugar sources.

An immunogen useful for treating malaria generally includes an immunogenic carrier and an antigenic malaria circumsporozoite protein (CSP) peptide that includes the peptide NANPNVDP (SEQ ID NO:2) linked to the immunogenic carrier. The immunogen may be administered to a subject having or at risk of having malaria. Alternatively, the immunogen may be administered to an individual having or at risk of having Plasmodium falciparum blood stage parasitemia. In some cases, the immunogen can be administered in combination with another therapeutic agent for treating malaria of Plasmodium falciparum blood stage parasitemia.

The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and / or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.

The invention belongs to the technical field of mosquito-borne infectious disease prevention and control, and provides an effect of human defensin in inhibition of anopheles sterneri malarial. According to the invention, the human defensin 5 is injected into the body of the anopheles stellari model by adopting a method for constructing the anopheles stellari infection model, and the influence of the human defensin 5 on the malarial transmission capability of the anopheles stellari is evaluated. Results show that after entering the mosquito body, the human defensin 5 inhibits the development of plasmodium johnsonii in the anopheles stersonii at an early stage by stimulating the innate immunity of the mosquito, so that the purpose of reducing the malarial transmission capability of the anopheles stersonii is achieved.